Abstract
Several laboratories have reported on the apoptotic potentials of human prostate cancer (PC) cell lines in response to crosslinking of Fas (CD95/APO-1) with agonistic anti-Fas antibodies. We have re-evaluated the apoptotic potentials of seven human PC cell lines using the natural Fas ligand (FasL) in place of agonistic antibody. First, PC cell lines were tested in a standard cytotoxicity assay with a transfected cell line that stably expresses human FasL. Next, we developed an adenoviral expression system employing 293 cells that stably express crmA, a poxvirus inhibitor of apoptosis, to analyze the effects of FasL when expressed internally by the PC cell lines. Our data suggest that the apoptotic potentials of these cell lines were greatly underestimated in previous studies utilizing agonistic anti-Fas antibodies. Lastly, adenoviral-mediated expression of FasL prevented growth and induced regression of two human PC cell lines in immunodeficient mice. These preliminary in vivo results suggest a potential use for adenovirus encoding FasL as a gene therapy for PC.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by J.C. Reed
Rights and permissions
About this article
Cite this article
Hedlund, T., Meech, S., Srikanth, S. et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 6, 175–182 (1999). https://doi.org/10.1038/sj.cdd.4400477
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400477
Keywords
This article is cited by
-
Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment
Cancer Immunology, Immunotherapy (2015)
-
FasL gene therapy: a new therapeutic modality for head and neck cancer
Cancer Gene Therapy (2006)
-
An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy
Journal of Molecular Medicine (2006)
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer
Cancer Gene Therapy (2005)
-
CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants
Oncogene (2003)